Relmada Therapeutics, Inc.
A Novel Therapy
for Compulsive Behaviors
Sepranolone is a novel clinical candidate targeting compulsive behaviors through modulation of GABAA receptor activity.
It is a synthetic analog of a naturally occurring antagonist of allopregnanolone (ALLO), a neurosteroid implicated in the regulation of anxiety, compulsivity, and appetite-related behaviors.
Mechanism of Action
GABA (γ-aminobutyric acid) is the primary inhibitory neurotransmitter in the brain and plays a central role in regulating mood, anxiety, and behavior.
In certain individuals, allopregnanolone (ALLO) can paradoxically exacerbate anxiety and compulsive behaviors rather than producing its typical calming effects.
Sepranolone is designed to selectively counteract these maladaptive effects, helping to normalize GABAA receptor signaling without disrupting baseline neurotransmission.
Clinical Rationale
Prior clinical and preclinical data support the potential for Sepranolone to have a beneficial effect on food craving, appetite and compulsive behaviors.
Its differentiated mechanism of action supports potential applicability across disorders characterized by dysregulated compulsivity and appetite signaling.
Prader-Willi Syndrome (PWS)
Sepranolone is advancing toward a Phase 2 clinical trial in Prader-Willi syndrome (PWS), with initiation expected in mid-2026.
PWS is a rare genetic disorder characterized by hyperphagia (chronic, insatiable hunger) and severe compulsive behaviors, resulting in significant long-term health and behavioral challenges.
The planned study is designed to evaluate the safety, tolerability, and effects of sepranolone on behavioral and appetite-related outcomes in this well-defined patient population.
For footnotes and references please see our latest Corporate Presentation on the Investors page.
